| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5759580 | ALLERGAN | Compositions containing micronized nebivolol |
Jun, 2015
(8 years ago) | |
| US6545040 | ALLERGAN | Method of lowering the blood pressure |
Dec, 2021
(2 years ago) | |
Bystolic is owned by Allergan.
Bystolic contains Nebivolol Hydrochloride.
Bystolic has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bystolic are:
- US5759580
- US6545040
Bystolic was authorised for market use on 17 December, 2007.
Bystolic is available in tablet;oral dosage forms.
Bystolic can be used as treatment of hypertension.
Drug patent challenges can be filed against Bystolic from 18 December, 2011.
The generics of Bystolic are possible to be released after 17 December, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2012 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2011
Market Authorisation Date: 17 December, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of BYSTOLIC before it's drug patent expiration?
More Information on Dosage
BYSTOLIC family patents
